ANNOUNCEMENT 01 Jun 2021

India has imposed a licensing requirement on exports of an antifungal medication.

NUMBER OF INTERVENTIONS

1

  • 1 harmful
  • 0 neutral
  • 0 liberalising
Inception date: 01 Jun 2021 | Removal date: open ended

Export licensing requirement

On 1 June 2021, the Indian Directorate General of Foreign Trade through Notification No. 07/2015-2020 amended the export policy of Amphotericin-B injections from "Free" to "Restricted". Goods with a "Restricted" export policy will require applying for a license before exports.

Amphotericin B is an antifungal medication that has seen an increase in demand in India due to fungal infections in COVID-19 patients.

AFFECTED SECTORS

 

AFFECTED PRODUCTS